<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022485</url>
  </required_header>
  <id_info>
    <org_study_id>CMG2020-32T</org_study_id>
    <nct_id>NCT05022485</nct_id>
  </id_info>
  <brief_title>Zimmer® Natural Nail® (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study</brief_title>
  <official_title>Anti-infective Noble Metal Alloy-coated Intramedullary Nail to Reduce Infection After Fracture Fixation: a Multicenter, Prospective Trial With a Retrospective Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this study is to compare fracture related infection (FRI) rates and show&#xD;
      superiority of ZNN Bactiguard Tibia over conventional uncoated titanium-alloy nails 12 months&#xD;
      after tibia fracture fixation.&#xD;
&#xD;
      The secondary objectives are confirmation of safety, performance and clinical benefits of ZNN&#xD;
      Bactiguard implant and related instrumentation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, Post-market Clinical Follow-up (PMCF) Study with&#xD;
      retrospective controls.&#xD;
&#xD;
      The study will enroll patients that will be implanted with the Zimmer Natural Nail Bactiguard&#xD;
      Tibia device and retrospective controls implanted with standard titanium-alloy tibia nails.&#xD;
&#xD;
      500 tibias will be recruited at maximum 15 sites and allocated on a 1:1 ratio into an:&#xD;
&#xD;
        -  investigational group (prospective/consecutive series of 250 tibias treated with ZNN&#xD;
           Bactiguard tibia)&#xD;
&#xD;
        -  a control group (retrospective series of 250 tibias treated with uncoated titanium-alloy&#xD;
           tibia nail - data collection will be retrospective, these subjects will not have to&#xD;
           undergo any study-related procedure).&#xD;
&#xD;
      The primary endpoint is the Fracture Related Infection (FRI) rate in the study population 12&#xD;
      months after fracture fixation.&#xD;
&#xD;
      The secondary endpoint is the confirmation of safety, performance and clinical benefits of&#xD;
      ZNN Bactiguard implant and related instrumentation through the following measure systems:&#xD;
&#xD;
        -  Radiologic (RUST) &amp; clinical (FIX-IT) fracture healing 12 months after fracture fixation&#xD;
           (performance).&#xD;
&#xD;
        -  Patients' outcomes assessed by the Oxford Knee Score 12 months after fracture fixation&#xD;
           (clinical benefits).&#xD;
&#xD;
        -  EQ5D-5L (patients' quality of life).&#xD;
&#xD;
        -  Incidence and frequency of adverse events (safety).&#xD;
&#xD;
      Data will be collected at 2 weeks, 3 months, 6 months and 1 year after fracture fixation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fracture related infection (FRI) rate in investigational and control group</measure>
    <time_frame>12 months after fracture fixation</time_frame>
    <description>FRI diagnosed according to the updated diagnostic algorithm drafted by the Fracture-Related Infection Consensus Group (Definition and diagnosis of fracture-related infection, M McNally,G Govaert, M Dudareva, M Morgenstern, W J Metsemakers, EFORT Open Rev 2020;5:614-619.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tibia fracture healing assessed radiologically through Radiographic Union Scale in Tibial fractures (RUST) score</measure>
    <time_frame>12 months after fracture fixation</time_frame>
    <description>The RUST score assigns each tibial cortex (anterior, posterior, medial and lateral) a score from 1 to 3, based on the appearance on the X-ray. The scores of all cortices combined will give a minimum score of 4 (definitely not healed) up to a maximum of 12 (completely healed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tibia fracture healing assessed clinically through the Function IndeX for Trauma (FIX-IT) score</measure>
    <time_frame>12 months after fracture fixation</time_frame>
    <description>The FIX-IT score assesses the subject's pain and ability to bear weight on lower extremity fractures. It ranges from 0 to 12 points, with 12 points representing the highest level of limb function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb functionality measured through the Oxford Knee Score</measure>
    <time_frame>12 months after fracture fixation</time_frame>
    <description>The Oxford Knee Score consists of twelve questions regarding knee functionality and pain. The score ranges from 12 to 60 points, with 12 points indicating the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of study participants assessed through the EQ-5D-5L questionnaire</measure>
    <time_frame>12 months after fracture fixation</time_frame>
    <description>The EQ-5D is a self-reported descriptive questionnaire about the patient's quality of life composed of 5 questions referring to mobility, self-care, daily activities, pain and anxiety/depression. Each question has 3 possible answers, which define the level of perceived problems (none, moderate,extreme problem)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequency of adverse events</measure>
    <time_frame>12 months after fracture fixation</time_frame>
    <description>Frequency and incidence of recorded AEs will be calculated</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Tibial Fractures</condition>
  <condition>Fracture Infection</condition>
  <arm_group>
    <arm_group_label>Investigational group</arm_group_label>
    <description>Subjects that will be implanted with the ZNN Bactiguard tibia device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Subjects that have received an uncoated titanium-alloy tibia nail in the past (data collection is retrospective; patients will not have to undergo any study-related procedure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ZNN Bactiguard tibia</intervention_name>
    <description>Tibia fracture fixation</description>
    <arm_group_label>Investigational group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        18-year-old patients or older with tibia fractures at high risk for infection (as defined&#xD;
        in the inclusion criteria) treated with a titanium-alloy intramedullary nail.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be 18 or older.&#xD;
&#xD;
          -  Patient has signed IRB/EC-approved informed consent (if applicable for retrospective&#xD;
             controls, based on local requirements).&#xD;
&#xD;
          -  Patient suffered primary tibia fracture (monolateral or bilateral) at high risk of&#xD;
             infection, eligible for fixation by intramedullary (IM) nailing (standard or&#xD;
             suprapatellar approach) and meets at least one of the following conditions:&#xD;
&#xD;
               -  Open fractures (incl. gunshot fractures): Gustilo Type I, II, III A and III B.&#xD;
&#xD;
               -  Delayed treatment (initial treatment by external fixation due to swelling/ high&#xD;
                  energy trauma followed by definitive treatment by intramedullary nail).&#xD;
&#xD;
               -  Fracture associated with ipsilateral leg compartment syndrome treated with&#xD;
                  fasciotomy wound(s).&#xD;
&#xD;
               -  Closed fractures with severe tissue damage: Tscherne grade C2 and C3.&#xD;
&#xD;
          -  Patient:&#xD;
&#xD;
               -  will be treated with ZNN Bactiguard tibia for inclusion in investigational group&#xD;
                  (retrospective enrollment is allowed up to 1st follow-up visit);&#xD;
&#xD;
               -  was treated with uncoated (conventional) titanium-alloy intramedullary tibia nail&#xD;
                  for inclusion in control group;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is unwilling or unable to give consent.&#xD;
&#xD;
          -  Patient is not expected to survive follow-up schedule.&#xD;
&#xD;
          -  Patient is anticipated to be non-compliant to the study protocol.&#xD;
&#xD;
          -  Patient has a mental or neurological condition or alcohol/drug addiction that will not&#xD;
             allow for proper informed consent and/or participation in follow-up program.&#xD;
&#xD;
          -  Patient is a prisoner.&#xD;
&#xD;
          -  Patient is known to be pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Patient suffered tibia fracture that meets any of the following conditions:&#xD;
&#xD;
               -  Pathologic fracture.&#xD;
&#xD;
               -  Gustilo Type IIIC open fracture.&#xD;
&#xD;
               -  Patient has multisegmented fracture NOT eligible for fixation by intramedullary&#xD;
                  nailing.&#xD;
&#xD;
               -  Patients with wound closure more than 10 days after injury.&#xD;
&#xD;
               -  Besides IM nail, patient requires additional tibia fixation by plate (additional&#xD;
                  tibia fixation by screw(s) and/or fibula plate fixation are allowed).&#xD;
&#xD;
               -  Concomitant with fracture, patient suffered head injury with Abbreviated Injury&#xD;
                  Score (AIS) ≥ 3.&#xD;
&#xD;
          -  For control group:&#xD;
&#xD;
               -  patient doesn't have all the minimum required data available:&#xD;
&#xD;
                    1. demographic information&#xD;
&#xD;
                    2. injury classification&#xD;
&#xD;
                    3. FRI information&#xD;
&#xD;
                    4. operative report and device information&#xD;
&#xD;
                    5. radiographic analyses (until fracture healing or confirmation of non-union&#xD;
                       leading to reoperation)&#xD;
&#xD;
          -  Tibia medullary canal is obliterated by a previous fracture or tumor*&#xD;
&#xD;
          -  Tibia bone shaft having excessive bow or a deformity*&#xD;
&#xD;
          -  Lack of bone substance or bone quality, which makes stable seating of the nail implant&#xD;
             impossible*&#xD;
&#xD;
          -  All concomitant diseases that can impair the operation, functioning or the success of&#xD;
             the nail implant*&#xD;
&#xD;
          -  Insufficient blood circulation*&#xD;
&#xD;
          -  Skeletally immature patients*&#xD;
&#xD;
          -  Infection*&#xD;
&#xD;
               -  ZNN Bactiguard tibia contraindication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Achakri</last_name>
    <role>Study Director</role>
    <affiliation>Clin Ops Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Rusconi</last_name>
    <phone>+41 798856425</phone>
    <email>paolo.rusconi@zimmerbiomet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Rohmer</last_name>
    <phone>+41 79 368 91 28</phone>
    <email>emilie.rohmer@zimmerbiomet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hesse</state>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonius Korschinsky, MD</last_name>
      <phone>+49 6421 58-64904</phone>
      <email>korschin@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Ruchholtz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Valle de Hebrón</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Yaiza Garcia</last_name>
      <email>yaiza.garcia@vhir.org</email>
    </contact>
    <investigator>
      <last_name>Jordi Teixidor Serra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Nik Kanakaris, MD</last_name>
      <email>n.kanakaris@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Peter Giannoudis, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intramedullary tibia nail</keyword>
  <keyword>Bactiguard</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

